Outcome measures in CIDP: A scoping and mapping review

Area of Science:

• Neurology
• Autoimmune Diseases
• Clinical Trials

Background:

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder with diverse symptoms.
• This heterogeneity complicates disease monitoring and treatment response assessment.
• Standardizing clinical outcome assessments (COAs) is crucial for managing CIDP.

Purpose of the Study:

• To conduct a comprehensive overview of COAs utilized in CIDP research.
• To identify and map COAs reported in scientific literature.
• To prioritize clinically relevant COAs for CIDP patients.

Main Methods:

• A structured literature review and mapping exercise was performed on CIDP publications from 2010-2023.
• Supplementary searches and expert consultation identified key historical and relevant COAs.
• Clinical experts prioritized identified COAs based on CIDP relevance.

Main Results:

• 99 distinct COAs were identified across 524 publications.
• Functional impairment and humanistic burden were the most frequent COA categories.
• INCAT (45.6%), MRC score (37.4%), and I-RODS (29.2%) were the most prominent COAs.

Conclusions:

• Significant heterogeneity exists in current CIDP COA usage.
• INCAT, I-RODS, and MRC score are core measures but do not cover all aspects of CIDP.
• Lack of validated biomarkers and COA heterogeneity impede CIDP treatment assessment, necessitating further research for comprehensive outcome measures.